This article discusses peptides as research compounds. It is not medical advice.
A clinician I spoke with recently described a patient who arrived at the clinic with a vial of semaglutide purchased from a compounding pharmacy, its labeling unclear and its origin uncertain. The patient had been using it for weight loss, unaware that the product differed from the FDA-approved formulation. This anecdote reflects a broader pattern emerging from recent reporting: as demand for GLP-1 receptor agonists surges, compounded versions are entering the market, and safety questions are multiplying.
A 2024 investigation by MedPage Today examined adverse event reports linked to compounded semaglutide, uncovering cases of dosing errors, contamination, and unexpected side effects. The findings have intensified scrutiny of compounding practices at a time when patients are increasingly turning to these alternatives due to cost and shortages. This article examines the research landscape for semaglutide and related peptides, focusing on what is known about their safety profiles, what gaps remain, and how to interpret the current evidence.
This article discusses peptides as research compounds. It is not medical advice.
What the MedPage Today Investigation Revealed
The MedPage Today report, published in early 2024, analyzed data from the FDA Adverse Event Reporting System (FAERS) and interviews with clinicians. It identified at least 10 cases of serious adverse events associated with compounded semaglutide, including severe gastrointestinal distress, hypoglycemia, and one instance of a patient injecting 10 times the intended dose due to labeling confusion. Unlike the FDA-approved pens, compounded versions often come in multi-dose vials requiring patient measurement, a step that introduces significant risk of error.
Compounding pharmacies are permitted to produce medications when FDA-approved drugs are in shortage, but they are not subject to the same manufacturing standards as pharmaceutical companies. The investigation highlighted that some compounding pharmacies use semaglutide sodium or semaglutide acetate, salt forms not found in the approved product and not studied for safety or efficacy in humans. A 2023 review in the Journal of the American Pharmacists Association warned that these salt forms may have different pharmacokinetic profiles, potentially altering drug absorption and effect (PubMed).
Regulatory actions have followed. In 2023, the FDA issued warning letters to several compounding pharmacies for producing semaglutide products with unverified purity and potency. The agency emphasized that compounded drugs lack the premarket review required for approved medications, leaving patients without assurance of quality. These enforcement actions underscore the legal and safety boundaries that researchers and clinicians must navigate when considering peptide compounds.
Research on Semaglutide as a Research Compound
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes and later approved for chronic weight management. Its research history is extensive. A 2021 trial published in the New England Journal of Medicine demonstrated that once-weekly subcutaneous semaglutide, combined with lifestyle intervention, resulted in a mean weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (PubMed). These findings established semaglutide as a potent metabolic research tool.
However, the research context differs sharply from the compounding landscape. In clinical trials, semaglutide is administered as a precisely dosed, preservative-free solution in a pre-filled pen. The peptide's stability, bioavailability, and safety profile were established under these controlled conditions. When researchers explore semaglutide in new contexts, such as combination therapies or novel delivery methods, they rely on pharmaceutical-grade material. A 2022 study investigating oral semaglutide's effects on cardiovascular outcomes used a rigorously manufactured formulation, reinforcing that research outcomes are tied to product integrity (PubMed).
The gap between research-grade semaglutide and compounded versions is significant. Compounded products may use different excipients, pH levels, or salt forms, all of which can alter the peptide's behavior. A 2022 review in Diabetes Care noted that even minor variations in formulation can affect immunogenicity, potentially leading to anti-drug antibodies that reduce efficacy or cause hypersensitivity (PubMed). For researchers, this underscores the importance of sourcing peptides from verified suppliers with documented purity and stability data.
Secondary Peptides in the Weight Loss Research Space
Beyond semaglutide, several other peptides are under investigation for metabolic and body composition effects, each with its own research profile and safety considerations.
AOD-9604 is a fragment of human growth hormone (hGH) that has been studied for its lipolytic properties. A 2019 trial examined AOD-9604 in obese subjects and found a modest reduction in fat mass without the adverse effects on glucose metabolism seen with full-length hGH (PubMed). However, the peptide is not FDA-approved, and long-term safety data are lacking. Research on AOD-9604 often involves oral or injectable formulations, and purity concerns similar to those with semaglutide apply to compounded versions. For those interested in combination research, a recent article on this site explores AOD-9604 and CJC-1295 stacks for body recomposition, highlighting the need for rigorous sourcing.
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that increases growth hormone secretion. A 2020 study in Clinical Endocrinology showed that CJC-1295 with DAC (drug affinity complex) significantly elevated IGF-1 levels over several days, suggesting potential for muscle growth and fat loss (PubMed). Yet, the prolonged half-life raises concerns about sustained growth hormone elevation, which could theoretically increase risks of insulin resistance or fluid retention. Research on CJC-1295 often uses lyophilized powder that must be reconstituted, a process prone to dosing errors if not performed with precision.
Hexarelin is a synthetic growth hormone secretagogue that also binds to the ghrelin receptor, potentially offering cardioprotective effects. A 2021 animal study reported that hexarelin improved cardiac function after myocardial infarction, but human data remain sparse (PubMed). Its safety profile in humans is not well-characterized, and the peptide is not approved for any clinical use. Researchers must consider the lack of toxicology data when designing studies.
Retatrutide and tirzepatide are newer multi-receptor agonists. Tirzepatide, a GIP/GLP-1 dual agonist, was approved in 2022 for diabetes and showed significant weight loss in trials. A 2023 study reported that tirzepatide led to a mean weight reduction of up to 22.5% in obese adults (PubMed). Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in phase 3 trials, with early data suggesting even greater weight loss. These compounds are only available as investigational drugs or approved products, not through compounding, but their emergence has fueled interest in peptide-based metabolic research.
What's Missing in the Current Evidence
Despite the growing body of research, significant gaps remain. For compounded semaglutide, there are no published clinical trials evaluating safety or efficacy. The FDA's adverse event reports are voluntary and likely undercount incidents. A 2023 analysis in JAMA Network Open estimated that only 1-10% of adverse events are captured by FAERS, meaning the true scope of harm from compounded peptides is unknown (PubMed).
For peptides like AOD-9604, CJC-1295, and hexarelin, the evidence base is thin. Most studies are small, short-term, and lack diverse populations. Long-term carcinogenicity, cardiovascular, and metabolic effects have not been assessed. The research community also lacks standardized protocols for purity testing and handling, which complicates cross-study comparisons. Without these data, it is difficult to draw firm conclusions about safety or therapeutic potential.
Regulatory gaps compound the problem. Compounding pharmacies operate under state boards of pharmacy, not the FDA, leading to inconsistent oversight. The FDA's ability to inspect and enforce is limited, especially for pharmacies that ship across state lines. A 2022 report from the Pew Charitable Trusts highlighted that many states do not require compounding pharmacies to report adverse events, creating a blind spot in the safety surveillance system (Pew).
How to Read the Research and Regulatory Landscape
For those navigating the peptide research field, a critical approach is essential. When evaluating a study, consider the source of the compound: was it pharmaceutical-grade or compounded? Look for details on purity, formulation, and storage. A 2021 commentary in Nature Reviews Endocrinology advised researchers to verify that peptides are accompanied by certificates of analysis and to use orthogonal analytical methods to confirm identity (PubMed).
Regulatory actions provide another lens. The FDA's warning letters often cite specific violations, such as using non-pharmaceutical-grade ingredients or making unsubstantiated claims. Reviewing these letters can reveal which practices are considered high-risk. For example, a 2023 warning letter to a compounding pharmacy noted that its semaglutide product was not sterile, a basic requirement for injectable drugs (FDA). Such details are instructive for researchers designing protocols that involve peptide handling.
It is also important to distinguish between peptides that are FDA-approved, those in clinical trials, and those that are purely research chemicals. Approved products have established safety profiles, while investigational drugs have some human data. Research chemicals like AOD-9604 and hexarelin have minimal human safety data and should be handled with heightened caution. The legal status of these compounds varies by jurisdiction, and researchers must ensure compliance with local regulations.
The Honest Answer About Peptide Safety
The current evidence does not support the safety of compounded semaglutide or unapproved peptides for human use outside of rigorous research settings. The MedPage Today findings are a reminder that when manufacturing standards are relaxed, patient harm can follow. For approved peptides like semaglutide and tirzepatide, the research supports their efficacy and safety when used as intended, but these benefits cannot be assumed for compounded versions.
For secondary peptides like AOD-9604, CJC-1295, and hexarelin, the honest answer is that we do not know enough. The available studies are preliminary, and the risk of adverse effects from impure or mislabeled products is real. Researchers interested in these compounds must invest in quality control and acknowledge the limitations of the data. The regulatory environment is evolving, but it currently leaves significant responsibility on the end user to verify product integrity.
If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
Common questions
What are the main risks of compounded semaglutide?
Compounded semaglutide may use salt forms not found in the approved product, leading to unknown pharmacokinetics. Dosing errors are common due to multi-dose vials and patient self-measurement. Contamination and lack of sterility assurance are additional risks. The FDA has issued warning letters to compounding pharmacies for these reasons. Adverse events reported include severe gastrointestinal issues and hypoglycemia. Without clinical trials, the safety profile of compounded semaglutide remains uncertain.
How does AOD-9604 differ from semaglutide in research?
AOD-9604 is a growth hormone fragment that targets fat metabolism, while semaglutide is a GLP-1 agonist that reduces appetite and slows gastric emptying. AOD-9604 has been studied for obesity but with less robust weight loss outcomes. It is not FDA-approved, and long-term safety data are lacking. Researchers should note that AOD-9604 does not affect glucose metabolism like full growth hormone, but its purity and sourcing are critical variables in any study.
Are there any approved alternatives to compounded semaglutide?
FDA-approved semaglutide products, such as Ozempic and Wegovy, are available by prescription. Tirzepatide (Mounjaro, Zepbound) is another approved option with dual GIP/GLP-1 activity. These medications have undergone rigorous testing for safety and efficacy. However, cost and insurance coverage can limit access. Patients should discuss these options with a healthcare provider rather than turning to unregulated compounded versions.
What should researchers look for when sourcing peptides?
Researchers should obtain peptides from suppliers that provide certificates of analysis with purity data, typically above 95%. Independent verification via mass spectrometry or HPLC is recommended. The peptide should be stored according to manufacturer guidelines, often lyophilized and protected from light and moisture. For injectable research, sterility and endotoxin testing are essential. Documentation of chain of custody and regulatory compliance can mitigate risks of adulterated products.
Why are compounding pharmacies allowed to make semaglutide?
When a drug is in shortage, the FDA permits compounding pharmacies to produce it to meet patient demand. Semaglutide has been on the FDA's drug shortage list intermittently since 2022. However, compounding is not intended for mass production, and the FDA has raised concerns about the scale and quality of some operations. State boards of pharmacy oversee these facilities, but oversight varies widely, leading to safety gaps.
This article discusses peptides as research compounds. It is not medical advice.